AbbVie (ABBV) and Regenxbio (RGNX) announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age-Related Macular Degeneration, Subretinal Delivery: Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are expected in 2026. ABBV-RGX-314 in Diabetic Retinopathy, Suprachoroidal Delivery: AbbVie and Regenxbio will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector to deliver gene therapy to the suprachoroidal space of the eye.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie sees $3.5B impairment charge related to emraclidine
- Drugmakers Raise the Prices on 583 Products to Start 2025
- AbbVie price target lowered to $211 from $215 at Truist
- AbbVie (ABBV) Lowers 2024 Earnings Outlook on Acquisition Costs
- AbbVie cuts Q4, FY24 adjusted EPS views due to acquisition expenses